Management der Primären Ciliären Dyskinesie

J. Raidt; J. Brillault; F. Brinkmann; A. Jung; C. Koerner-Rettberg; A. Koitschev; H. Linz-Keul; T. Nüßlein; F. C. Ringshausen; J. Röhmel; M. Rosewich; C. Werner; H. Omran

doi:10.1055/a-1235-1520

Pneumologie, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Pneumologie 2020; 74(11): 750-765
DOI: 10.1055/a-1235-1520

Übersicht

Management der Primären Ciliären Dyskinesie

Management of Primary Ciliary Dyskinesia

J. Raidt

¹Klinik für Kinder- und Jugendmedizin, Allgemeine Pädiatrie, Universitätsklinikum Münster, Münster

,

J. Brillault

²Kartagener Syndrom & Primäre Ciliäre Dyskinesie e. V., Herbolzheim

,

F. Brinkmann

³Pädiatrische Pneumologie und CF-Centrum, Universitätsklinik für Kinder- und Jugendmedizin Bochum, Bochum

,

A. Jung

⁴Abteilung für Pneumologie, Universitäts-Kinderspital Zürich, Zürich, Schweiz

,

C. Koerner-Rettberg

⁵Klinik für Kinder- und Jugendmedizin, Marien-Hospital Wesel, Wesel

,

A. Koitschev

⁶Abteilung Pädiatrische HNO-Heilkunde und Otologie, Olgahospital, Klinikum Stuttgart, Stuttgart

,

H. Linz-Keul

⁷Physiotherapiepraxis, Bad Kissingen

,

T. Nüßlein

⁸Klinik für Kinder- und Jugendmedizin Koblenz, Gemeinschaftsklinikum Mittelrhein, Koblenz

,

F. C. Ringshausen

⁹Klinik für Pneumologie, Medizinische Hochschule Hannover (MHH), Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Deutsches Zentrum für Lungenforschung (DZL), Hannover

,

J. Röhmel

¹⁰Klinik für Pädiatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin, Berlin

,

M. Rosewich

¹¹Kinderarztpraxis, Oberursel,

,

C. Werner

¹²Kinder- und Jugendmedizin, Helios Kliniken Schwerin, Schwerin

,

H. Omran

¹Klinik für Kinder- und Jugendmedizin, Allgemeine Pädiatrie, Universitätsklinikum Münster, Münster

› Institutsangaben

Abstract

Zusammenfassung

Die Primäre Ciliäre Dyskinesie (PCD, MIM 242650) ist eine seltene hereditäre Multisystemerkrankung mit klinisch heterogenem Phänotyp. Leitsymptom ist eine chronische Sekretretention der oberen und unteren Atemwege, welche durch die Dysfunktion motiler respiratorischer Zilien entsteht. In der Folge kommt es zur Ausbildung von Bronchiektasen, häufig zu einer Infektion durch Pseudomonas aeruginosa sowie einer abnehmenden Lungenfunktion bis hin zum Lungenversagen.

Bislang gibt es kaum evidenzbasierte Therapieempfehlungen, da randomisierte Langzeitstudien zur Behandlung der PCD fehlten. In diesem Jahr wurden die Daten einer ersten placebokontrollierten Medikamentenstudie bei PCD veröffentlicht. Anlässlich dieses Meilensteins im Management der PCD wurde der vorliegende Übersichtsartikel als Konsens von Patientenvertretern sowie Klinikern, die langjährige Erfahrung in der Behandlung der PCD haben, verfasst. Diese Arbeit bietet eine Zusammenfassung aktuell eingesetzter Behandlungsverfahren, die überwiegend auf persönlichen Erfahrungen und Expertenmeinungen beruhen oder von anderen Atemwegserkrankungen wie der Cystischen Fibrose (CF), COPD oder Bronchiektasen-Erkrankung abgeleitet werden. Da es derzeit keine kurative Therapie für PCD gibt, stehen symptomatische Maßnahmen wie die regelmäßige Reinigung der Atemwege und die Behandlung von rezidivierenden Atemwegsinfektionen im Fokus. Nicht respiratorische Manifestationen werden organspezifisch behandelt. Um neben der ersten Medikamentenstudie mehr evidenzbasiertes Wissen zu generieren, werden weitere Projekte etabliert, u. a. ein internationales PCD-Register. Hierüber wird Patienten der Zugang zu klinischen und wissenschaftlichen Studien erleichtert und die Vernetzung behandelnder Zentren gefördert. Des Weiteren können Erkenntnisse über eine Genotyp-spezifische Erkrankungsschwere erlangt werden, um folglich die therapeutische Versorgung der Patienten zu verbessern und somit zu individualisieren.

Abstract

Primary Ciliary Dyskinesia (PCD, MIM 242650) is a rare, hereditary multiorgan disease characterized by malfunction of motile cilia. Hallmark symptom is a chronic airway infection due to mucostasis leading to irreversible lung damage that may progress to respiratory failure. There is no cure for this genetic disease and evidence-based treatment is limited. Until recently, there were no randomized controlled trials performed in PCD, but this year, data of the first placebo-controlled trial on pharmacotherapy in PCD were published. This cornerstone in the management of PCD was decisive for reviewing currently used treatment strategies. This article is a consensus of patient representatives and clinicians, which are highly experienced in care of PCD-patients and provides an overview of the management of PCD. Treatments are mainly based on expert opinions, personal experiences, or are deduced from other lung diseases, notably cystic fibrosis (CF), COPD or bronchiectasis. Most strategies focus on routine airway clearance and treatment of recurrent respiratory tract infections. Non-respiratory symptoms are treated organ specific. To generate further evidence-based knowledge, other projects are under way, e. g. the International PCD-Registry. Participating in patient registries facilitates access to clinical and research studies and strengthens networks between centers. In addition, knowledge of genotype-specific course of the disease will offer the opportunity to further improve and individualize patient care.

Volltext

Referenzen

Literatur
1 Afzelius BA. A human syndrome caused by immotile cilia. Science 1976; 193: 317-319
2 Shapiro AJ, Davis SD, Ferkol T. et al. Laterality Defects Other Than Situs Inversus Totalis in Primary Ciliary Dyskinesia. Chest 2014; 146: 1176-1186
3 Barbato A, Frischer T, Kuehni CE. et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009; 34: 1264-1276
4 Lucas JS, Barbato A, Collins SA. et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601090
5 Werner C, Onnebrink JG, Omran H. Diagnosis and management of primary ciliary dyskinesia. Cilia 2015; 4: 2
6 Mirra V, Werner C, Santamaria F. Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment Strategies. Front Pediatr 2017; 5: 135
7 Strippoli M-PF, Frischer T, Barbato A. et al. Management of primary ciliary dyskinesia in European children: recommendations and clinical practice. Eur Respir J 2012; 39: 1482-1491
8 Nüßlein T, Brinkmann F, Ahrens P. et al. Diagnostik der Primären Ciliären Dyskinesie. Empfehlungen in Zusammenarbeit mit Kartagener-Syndrom und Primäre Ciliäre Dyskinesie e. V. Monatszeitschrift Kinderheilkd 2013; 161: 404-416
9 Shapiro AJ, Zariwala MA, Ferkol T. et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol 2016; 51: 115-132
10 Rowe SM, Daines C, Ringshausen FC. et al. Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017; 377: 2024-2035
11 Kennedy MP, Noone PG, Leigh MW. et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007; 188: 1232-1238
12 Montella S, Maglione M, Bruzzese D. et al. Magnetic resonance imaging is an accurate and reliable method to evaluate non-cystic fibrosis paediatric lung disease. Respirology 2012; 17: 87-91
13 Maglione M, Montella S, Santamaria F. Chest CTs in primary ciliary dyskinesia: not too few, but not too many!. Pediatr Pulmonol 2012; 47: 733-735
14 Lucas JS, Burgess A, Mitchison HM. et al. Diagnosis and management of primary ciliary dyskinesia. Arch Dis Child 2014; 99: 850-856
15 Noone PG, Leigh MW, Sannuti A. et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169: 459-467
16 Rogers GB, Carroll MP, Zain NMM. et al. Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia. J Clin Microbiol 2013; 51: 4029-4035
17 Knowles MR, Daniels LA, Davis SD. et al. Primary Ciliary Dyskinesia. Recent Advances in Diagnostics, Genetics, and Characterization of Clinical Disease. Am J Respir Crit Care Med 2013; 188: 913-922
18 Marthin JK, Petersen N, Skovgaard LT. et al. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181: 1262-1268
19 Green K, Buchvald FF, Marthin JK. et al. Ventilation inhomogeneity in children with primary ciliary dyskinesia. Thorax 2012; 67: 49-53
20 Miller MR, Hankinson J, Brusasco V. et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338
21 Boon M, Vermeulen FL, Gysemans W. et al. Lung structure-function correlation in patients with primary ciliary dyskinesia. Thorax 2015; 70: 339-345
22 Irving SJ, Ives A, Davies G. et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med 2013; 188: 545-549
23 Nyilas S, Schlegtendal A, Yammine S. et al. Further evidence for an association between LCI and FEV1 in patients with PCD. Thorax 2015; 70: 896
24 Nyilas S, Bauman G, Pusterla O. et al. Structural and Functional Lung Impairment in Primary Ciliary Dyskinesia. Assessment with Magnetic Resonance Imaging and Multiple Breath Washout in Comparison to Spirometry. Ann Am Thorac Soc 2018; 15: 1434-1442
25 Brown DE, Pittman JE, Leigh MW. et al. Early lung disease in young children with primary ciliary dyskinesia. Pediatr Pulmonol 2008; 43: 514-516
26 Santamaria F, Montella S, Tiddens HAWM. et al. Structural and Functional Lung Disease in Primary Ciliary Dyskinesia. Chest 2008; 134: 351-357
27 Montella S, Santamaria F, Salvatore M. et al. Assessment of chest high-field magnetic resonance imaging in children and young adults with noncystic fibrosis chronic lung disease: comparison to high-resolution computed tomography and correlation with pulmonary function. Invest Radiol 2009; 44: 532-538
28 Dettmer S, Ringshausen F, Vogel-Claussen J. et al. Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings. PLoS One 2018; 13: e0191457
29 Chalmers JD, Elborn JS. Reclaiming the name ‘bronchiectasis’. Thorax 2015; 70: 399-400
30 Wielpütz MO, Puderbach M, Kopp-Schneider A. et al. Magnetic Resonance Imaging Detects Changes in Structure and Perfusion, and Response to Therapy in Early Cystic Fibrosis Lung Disease. Am J Respir Crit Care Med 2014; 189: 956-965
31 Stahl M, Wielpütz MO, Graeber SY. et al. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children With Cystic Fibrosis. Am J Respir Crit Care Med 2016;
32 Sommer JU, Schäfer K, Omran H. et al. ENT manifestations in patients with primary ciliary dyskinesia: prevalence and significance of otorhinolaryngologic co-morbidities. Eur Arch Otorhinolaryngol 2011; 268: 383-388
33 Morgan LC, Birman CS. The impact of Primary Ciliary Dyskinesia on the upper respiratory tract. Paediatr Respir Rev 2016; 18: 33-38
34 Raidt J, Werner C. Chronic rhinosinusitis in non-cystic fibrosis bronchiectasis and primary ciliary dyskinesia. ERS Monogr 2017; 76: 148-161
35 Fokkens WJ, Lund VJ, Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinol J 2020; 58: 1-464
36 Hentschel J, Müller U, Doht F. et al. Influences of nasal lavage collection-, processing- and storage methods on inflammatory markers – Evaluation of a method for non-invasive sampling of epithelial lining fluid in cystic fibrosis and other respiratory diseases. J Immunol Methods 2014; 404: 41-51
37 Kellett F, Robert NM. Nebulised 7 % hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105: 1831-1835
38 Kuehni CE, Goutaki M, Kobbernagel HE. Hypertonic saline in patients with primary ciliary dyskinesia: on the road to evidence-based treatment for a rare lung disease. Eur Respir J 2017; 49: 1602514
39 De Boeck K, Haarman E, Hull J. et al. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial. J Cyst Fibros 2017; 16: 380-387
40 Bilton D, Daviskas E, Anderson SD. et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225
41 Fuchs HJ, Borowitz DS, Christiansen DH. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642
42 O’Donnell AE, Barker AF, Ilowite JS. et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329-1334
43 Wilkinson M, Sugumar K, Milan SJ. et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2014;
44 Polverino E, Goeminne PC, McDonnell MJ. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629
45 Madsen A, Green K, Buchvald F. et al. Aerobic Fitness in Children and Young Adults with Primary Ciliary Dyskinesia. PLoS One 2013; 8: e71409
46 Phillips GE, Thomas S, Heather S. et al. Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge. Eur Respir J 1998; 11: 1389-1391
47 Alanin MC, Nielsen KG, von Buchwald C. et al. A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. Clin Microbiol Infect 2015; 21: 1093.e1-1097
48 O’Donnell AE, Aksamit TR. 3rd World Bronchiectasis Conference. Chronic Obstr Pulm Dis J COPD Found 2018; 5: 302-323
49 Eden E, Choate R, Barker A. et al. The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis J COPD Found 2019; 6: 145-153
50 Lucas JS, Gahleitner F, Amorim A. et al. Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials. ERJ Open Res 2019; 5: 00147-02018
51 Flume PA, O’Sullivan BP, Robinson KA. et al. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med 2007; 176: 957-969
52 King PT, Holmes PW. Use of antibiotics in bronchiectasis. Rev Recent Clin Trials 2012; 7: 24-30
53 Marchant J, Masters IB, Champion A. et al. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax 2012; 67: 689-693
54 Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013; 22: 205-216
55 Hill AT, Pasteur M, Cornford C. et al. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20: 135-140
56 Schwarz C, Schulte-Hubbert B, Bend J. et al. S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa. Pneumologie 2018; 72: 347-392
57 Crowley S, Holgersen MG, Nielsen KG. Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers. Chron Respir Dis 2019; 16: 147997231878791
58 Maglione M, Bush A, Nielsen KG. et al. Multicenter analysis of body mass index, lung function, and sputum microbiology in primary ciliary dyskinesia. Pediatr Pulmonol 2014; 49: 1243-1250
59 Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A. et al. Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia. Respir Med 2017; 131: 241-246
60 Araújo D, Shteinberg M, Aliberti S. et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51: 1701953
61 Pasteur MC, Bilton D, Hill AT. et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: 577-577
62 Serisier DJ, Bilton D, De Soyza A. et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817
63 Wong C, Jayaram L, Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2012; 380: 660-667
64 Altenburg J, de Graaff CS, Stienstra Y. et al. Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis. JAMA 2013; 309: 1251
65 Mogayzel PJ, Naureckas ET, Robinson KA. et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187: 680-689
66 Kelly C, Chalmers JD, Crossingham I. et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018; 3: CD012406
67 Kobbernagel HE, Buchvald FF, Haarman EG. et al. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med 2016; 16: 104
68 Kobbernagel HE, Buchvald FF, Haarman EG. et al. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2020; 8: 493-505
69 Ringshausen FC, de Roux A, Rademacher J. Bronchiektasen: Vielfach unterschätzt. Dtsch Arztebl 2016; 113: [4]
70 Quon BS, Goss CH, Ramsey BW. Inhaled Antibiotics for Lower Airway Infections. Ann Am Thorac Soc 2014; 11: 425-434
71 Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014; 44: 382-393
72 Orriols R, Hernando R, Ferrer A. et al. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respiration 2015; 90: 299-305
73 Haworth CS, Foweraker JE, Wilkinson P. et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982
74 Murray MP, Govan JRW, Doherty CJ. et al. A Randomized Controlled Trial of Nebulized Gentamicin in Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499
75 Ratjen F, Moeller A, McKinney ML. et al. Eradication of early P. aeruginosa infection in children. J Cyst Fibros 2019; 18: 78-85
76 Wiesemann HG, Steinkamp G, Ratjen F. et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92
77 Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420-1426
78 Yiallouros PK, Kouis P, Middleton N. et al. Clinical features of primary ciliary dyskinesia in Cyprus with emphasis on lobectomized patients. Respir Med 2015; 109: 347-356
79 Hayes D, Reynolds SD, Tumin D. Outcomes of lung transplantation for primary ciliary dyskinesia and Kartagener syndrome. J Hear Lung Transplant 2016; 35: 1377-1378
80 Macchiarini P, Chapelier A, Vouhé P. et al. Double lung transplantation in situs inversus with Kartagener’s syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg 1994; 108: 86-91
81 Deuse T, Reitz BA. Heart-lung transplantation in situs inversus totalis. Ann Thorac Surg 2009; 88: 1002-1003
82 Gauthier JM, Takahashi T, Bierhals AJ. et al. Technical Considerations for Lung Transplantation in Kartagener’s Syndrome. Ann Thorac Surg 2019; 107: e337-e339
83 Campbell R. Managing upper respiratory tract complications of primary ciliary dyskinesia in children. Curr Opin Allergy Clin Immunol 2012; 12: 32-38
84 Andersen TN, Alanin MC, von Buchwald C. et al. A longitudinal evaluation of hearing and ventilation tube insertion in patients with primary ciliary dyskinesia. Int J Pediatr Otorhinolaryngol 2016; 89: 164-168
85 Campbell RG, Birman CS, Morgan L. Management of otitis media with effusion in children with primary ciliary dyskinesia: a literature review. Int J Pediatr Otorhinolaryngol 2009; 73: 1630-1638
86 Majithia A, Fong J, Hariri M. et al. Hearing outcomes in children with primary ciliary dyskinesia -- a longitudinal study. Int J Pediatr Otorhinolaryngol 2005; 69: 1061-1064
87 Mener DJ, Lin SY, Ishman SL. et al. Treatment and outcomes of chronic rhinosinusitis in children with primary ciliary dyskinesia: where is the evidence? A qualitative systematic review. Int Forum Allergy Rhinol 2013; 3: 986-991
88 Wolter NE, Dell SD, James AL. et al. Middle ear ventilation in children with primary ciliary dyskinesia. Int J Pediatr Otorhinolaryngol 2012; 76: 1565-1568
89 Fokkens WJ, Lund VJ, Mullol J. et al. European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinol Suppl 2012; 23: 1-298
90 Mainz JG, Hentschel J, Schien C. et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros 2012; 11: 158-161
91 Mainz JG, Schaedlich K, Schien C. et al. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther 2014; 8: 209-217
92 Alanin MC, Johansen HK, Aanaes K. et al. Simultaneous sinus and lung infections in patients with primary ciliary dyskinesia. Acta Otolaryngol 2015; 135: 58-63
93 Alanin MC, Aanaes K, Høiby N. et al. Sinus surgery can improve quality of life, lung infections, and lung function in patients with primary ciliary dyskinesia. Int Forum Allergy Rhinol 2017; 7: 240-247
94 Mainz JG, Gerber A, Lorenz M. et al. Pseudomonas aeruginosa Acquisition in Cystic Fibrosis Patients in Context of Otorhinolaryngological Surgery or Dentist Attendance: Case Series and Discussion of Preventive Concepts. Case Rep Infect Dis 2015; 2015: 1-9
95 Bequignon E, Dupuy L, Zerah-Lancner F. et al. Critical Evaluation of Sinonasal Disease in 64 Adults with Primary Ciliary Dyskinesia. J Clin Med 2019; 8: 619
96 Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol Cell Biol 2007; 8: 880-893
97 Vanaken GJ, Bassinet L, Boon M. et al. Infertility in an adult cohort with primary ciliary dyskinesia: phenotype-gene association. Eur Respir J 2017; 50: 1700314
98 Afzelius BA. Cilia-related diseases. J Pathol 2004; 204: 470-477
99 Afzelius BA, Eliasson R. Male and female infertility problems in the immotile-cilia syndrome. Eur J Respir Dis Suppl 1983; 127: 144-147
100 Blyth M, Wellesley D. Ectopic pregnancy in primary ciliary dyskinesia. J Obstet Gynaecol 2008; 28: 358
101 Raidt J, Werner C, Menchen T. et al. Ciliary function and motor protein composition of human fallopian tubes. Hum Reprod 2015; 30: 2871-2880
102 Lin TK, Lee RK, Su JT. et al. A successful pregnancy with in vitro fertilization and embryo transfer in an infertile woman with Kartagener’s syndrome: a case report. J Assist Reprod Genet 1998; 15: 625-627
103 Sha Y-W, Ding L, Li P. Management of primary ciliary dyskinesia/Kartagener’s syndrome in infertile male patients and current progress in defining the underlying genetic mechanism. Asian J Androl 2014; 16: 101-106
104 Goss CH, Rubenfeld GD, Otto K. et al. The Effect of Pregnancy on Survival in Women With Cystic Fibrosis. Chest 2003; 124: 1460-1468
105 Giordani B, Quattrucci S, Amato A. et al. A case-control study on pregnancy in Italian Cystic Fibrosis women. Data from the Italian Registry. Respir Med 2018; 145: 200-205
106 Harrison MJ, Shapiro AJ, Kennedy MP. Congenital Heart Disease and Primary Ciliary Dyskinesia. Paediatr Respir Rev 2016; 18: 25-32
107 Lee L. Riding the wave of ependymal cilia: Genetic susceptibility to hydrocephalus in primary ciliary dyskinesia. J Neurosci Res 2013; 91: 1117-1132
108 Wallmeier J, Frank D, Shoemark A. et al. De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry. Am J Hum Genet 2019; 105: 1030-1039
109 Ibanez-Tallon I, Heintz N, Omran H. To beat or not to beat: roles of cilia in development and disease. Hum Mol Genet 2003; 12: 27R-35
110 Budny B, Chen W, Omran H. et al. A novel X-linked recessive mental retardation syndrome comprising macrocephaly and ciliary dysfunction is allelic to oral-facial-digital type I syndrome. Hum Genet 2006; 120: 171-178
111 Jung A, Heinrichs I, Geidel C. et al. Inpatient paediatric rehabilitation in chronic respiratory disorders. Paediatr Respir Rev 2012; 13: 123-129
112 Simon A. Anforderungen an die Hygiene bei der medizinischen Versorgung von Patienten mit Cystischer Fibrose (Mukoviszidose). RKI 2012;